Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

Earlier this month an approval for Novartis's CDK inhibitor Kisqali gave it a leg up over Eli Lilly's Verzenio. Roche has a number of drugs in the market for breast cancer, but this would be its ...

the most common second-line strategies were a CDK4/6 inhibitor plus endocrine therapy (34.6%), single-agent endocrine therapy (30.9%), and chemotherapy (29.4%). By contrast, subsequent treatment ...

This article explores the potential of oral chemotherapeutic agents, with a focus on taxane-based regimens. Combination with a P-gp inhibitor is one method to overcome problems with the ...

When added to standard treatment with hormone-based drugs, Ibrance (palbociclib ... “inform the development of our next-generation CDK inhibitors in early breast cancer,” according to Chris ...

Each year, two million individuals are diagnosed with breast cancer, resulting in over 685,000 deaths worldwide 1. Although breast cancer is the most commonly diagnosed cancer globally 2, each ...

The randomized phase 3 PATINA trial is the first phase 3 study to show the benefit of cyclin-dependent kinase (CDK ... CDK4/6 inhibitor in combination with endocrine therapy and anti-HER2 drugs ...